

MedStar Medicare Choice Pharmacy Services Phone: 855-266-0712

Fax: 855-862-6517

Revised: 10/2016

			Pri	TECF or Author		ERA ation Form						
□ Standard Request (72 hou □ Expedited Request (24 ho	lity to reque	rescriber believe that waiting 72 hours for a standard decision could seriously harm your life, y to regain maximum function, you can request an expedited decision. For expedited requests a decision within 24 hours. You cannot request an expedited coverage determination if you are abursement for a drug you already received.										
				Demog	jra	phics						
Patient Information Prescr									iber Information			
Patient Name:					Prescriber Name:							
DOB:			Age:		NPI#:			Specialty:				
Health Plan ID#:						Phone:			Fax:			
Pharmacy Name:		Pharm	Pharmacy Phone:		Office Contact:			Direct Phone # or Ext:				
			Me	dication	ln	formation						
Drug Requested:	Strengt	th:			Directions:		Qu	antity		Day Supply:		
Tecfidera	<ul> <li>□ 120mg Delayed-Release Capsule</li> <li>□ 240mg Delayed-Release Capsule</li> <li>□ 30 Day Starter Pack</li> </ul>				Disp			spensed:				
<ul><li>□ New medication</li><li>□ Continuation of therapy</li></ul>	Start Date:  If this is continuation of therapy, please provide CHART DOCUMENTATION indicating the member showed improvement while on therapy.											
			C	Clinical In	nfo	rmation						
Diagnosis:						Da	Date Diagnosed:					
Does the member have relapsing/remitting form of Multiple Sclerosis?							Yes	□ No				
Did the member have a recent (within the past 6 months) complete blood count (CBC)?  If yes, please indicate date:								Yes	□ No			
Does the member have current evidence of active infection?							Yes	□ No				
Is the member on concomitant therapy with antineoplastic, immunosuppressive therapy, or immune modulating therapies?  If yes, please document in the medication history below.								Yes	□ No			

Is this a REAUTHORIZAT	ΓΙΟΝ request?		□ <b>Y</b>	'es	□ No	
immune modulatir ✓ Documentation of ✓ Documentation th Date of last test:_	nowing members at the member is at the member is no therapies.  no active infection at the member's	S <u>NOT</u> on concomit on lymphocyte levels	tant therapy with	antineoplastic	, imm	unosuppressive, or
□ No other medications ha				oro coman		
Medication	Strength	Directions	Dates of <sup>-</sup> Start	Therapy End	Re	eason for Discontinuing
Please provide any	/ additional ii	nformation wh	ich should b	e considere	d in	the space below: